Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.79 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.79 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9384136 | 0.99 | ADRA2A (0.77) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9380820 | 0.88 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL8605175 | 0.88 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9380868 | 0.88 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9377952 | 0.87 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9536107 | 0.87 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9380512 | 0.87 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9383736 | 0.87 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9534711 | 0.86 | ADRA2A (0.77) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9379609 | 0.86 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0344981-B1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1989012053-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | claimed |
| EP-0663014-B1 | DNA ENCODING HUMAN ALPHA 1 ADRENERGIC RECEPTORS AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6602888-B2 | Binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20030113772-A1 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030113771-A1 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6448011-B1 | ISOLATED NUCLEIC ACID, VECTORS, TRANSFORMED MAMMALIAN CELLS AND NON-HUMAN TRANSGENIC ANIMALS THAT ENCODE AND EXPRESS NORMAL OR MUTANT ADRENERGIC RECEPTOR GENES. | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | H. LUNDBECK A/S (DK) | 2002-03-14 | — | — | US | disclosed |
| EP-1063292-A2 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | Synaptic Pharmaceutical Corporation (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1063291-A2 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | Synaptic Pharmaceutical Corporation (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-0384677-B1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5006521-A | α-adrenergic receptor antagonists and methods of use thereas | SMITHKLINE BEECHAM CORPORATION (US) | 1991-04-09 | — | — | US | disclosed |
| US-4981848-A | CARDIOVASCULAR, HYPOTENSIVE, ANTIDEPRESSANT | SMITHKLINE BEECHAM CORPORATION (US) | 1991-01-01 | — | — | US | disclosed |
| US-4963547-A | HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0384677-A1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-08-29 | — | — | EP | disclosed |
| WO-1989012054-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012053-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344981-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | ADRB1, ADRA1B, ADRA1A | ADRA2A 9/4885ADRA2B 6/4885ADRA2C 8/4885 |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | ADRB1, ADRA1B, ADRA1A | ADRA2A 9/4885ADRA2B 5/4885ADRA2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.